KIT and neoplasm: Delanzomib treatment over the course of three weeks resulted in significant tumor reduction comparable to imatinib treatment in the IM-sensitive patient-derived UZLX-GIST1 model (KIT p.V560D) (Fig. 5A; Suppl.